Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis

Sponsor
Far Eastern Memorial Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01159197
Collaborator
(none)
100
1
1
13
7.7

Study Details

Study Description

Brief Summary

Background

More than 50% of dialysis patients experience sleep disturbances that significantly affect quality of life, overall morbidity, and mortality. There is no effective therapy except hypnotics, which have notable side effects. Cognitive-behavioral therapy (CBT) is effective for treating peritoneal dialysis (PD) patients, the elderly and cancer patients with chronic insomnia, but its effectiveness has never been reported in hemodialysis (HD) patients and its impacts on the inflammatory cytokines, oxidative stress and autonomic dysfunction in this population are unknown. The investigators investigated the effectiveness of CBT in HD patients by assessing changes in sleep quality, inflammatory cytokines, oxidative stress and autonomic dysfunction.

Objects

This study is designed to assess the effectiveness of CBT on sleep disturbance in insomnias HD patients. The investigators also evaluate the impacts of CBT on the inflammatory cytokines, oxidative stress and autonomic dysfunction in these insomnias HD patients.

Methods

The investigators expected to recruit 80 insomnias HD patients undergoing maintenance HD for more than 3 months for the investigation. Besides, 40 HD patients without sleep disturbance will be recruited for comparison. Patients with sleep disturbance (N=80) was randomized to either intervention (CBT) group (N=40) or control group (N=40). Participants in CBT group will receive 6-week CBT while in control group and patients without sleep disturbance only receive sleep hygiene education. The subjects were assessed at baseline and after the intervention with the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Beck depression index (BDI) and the International Index of Erectile Function (IIEF) for men and the Index of Female Sexual Function (IFSF) for women; and inflammatory cytokines (serum IL-1β, IL-18, and TNF-α levels), oxidative stress (TBARS, Total antioxidant status and serum 8-OHdG) and autonomic dysfunction (Baroreflex sensitivity, BRS) were measured.

Expected results

The investigators expect that CBT can improve the sleep disturbance in HD patients and may change the inflammatory cytokines, oxidative stress and autonomic dysfunction after the intervention in insomnias HD patients.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: cognitive behavioral therapy
N/A

Detailed Description

Sleep disturbance is common in patients with renal disease. According to previous studies, it occurs in more than 50% of chronic kidney disease (CKD) patients and those undergoing dialysis. 1, 2 Insomnia, restless legs syndrome (RLS), daytime sleepiness, and sleep apnea syndrome are common complaints; such sleep disturbances significantly affect the quality of life, overall morbidity, hospitalization, and mortality. 3-5 The main remedy for sleep disturbances, hypnotics, have notable side effects such as daytime sleepiness, psychological dependence, and drug-to-drug interactions, which make these drugs less than an optimal therapy. 6 Cognitive-behavioral therapy (CBT), the most widely used psychological intervention for insomnia, combines cognitive strategies such as stimulus control and relaxation training and has been proven to be effective for chronic insomnia in the elderly, cancer patients, and chronic pain sufferers7, 8. In most published articles CBT has been reported be superior to pharmacological and other behavioral therapies.9 In our previous investigation10, we found that the CBT was effective in PD patients with sleep disturbance presented with declined of Pittsburgh Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS); furthermore, the inflammatory cytokines, such as IL-1β, IL-18, TNF-α also declined after CBT in those insomnias PD patients. In previous studies, changes in cytokine release correlated with insomnia in patients undergoing hemodialysis11 or with breast cancer.12 Nevertheless, the effectiveness of CBT of sleep disturbance in insomnias HD patients is still not known.

In this study, we investigated the effectiveness of CBT for treatment of HD patients with insomnia by assessing changes in sleep quality subjectively through self-report questionnaires. The purpose of this study was to identify new therapeutic options for sleep disorders beyond hypnotics in HD patients. Because the association of sleep disturbance, oxidative stress and autonomic dysfunction in general population and patient with sleep apnea were demonstrated in previous investigations, we also investigate the possible impacts of CBT on the oxidative stress, autonomic dysfunction in these patients.

This study is designed to:
  1. To evaluate the effectiveness of CBT for sleep disturbance in maintenance HD patients.

  2. To evaluate the possible impacts of CBT on inflammatory cytokines, oxidative stress and autonomic dysfunction in insomnias HD patients. .

  3. To compare the systemic inflammation, oxidative stress and autonomic dysfunction in HD patients with and without sleep disturbance.

Study designs and methods Eighty ESRD patients undergoing maintenance hemodialysis (HD) for more than 6 months with subjective complaint of sleep disturbance and screening PSQI ≥ 5 will be recruited for the investigation. Besides, 40 ESRD patients undergoing HD for more than 6 months without sleep disturbance will also be recruited as the population-base control group. Insomnias HD patients (N=80) will be randomized into interventional group (CBT group) and control group in 1:1 ratio in the following 6-week trial.

All participants (N=120) will receive questionnaires including Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Beck depression index (BDI) and the International Index of Erectile Function (IIEF) for men and the Index of Female Sexual Function (IFSF) and check-ups of baroreflex sensitivity (BRS) for autonomic dysfunction before the trial. Also, all of them will get fasting blood sampling at the initiation of trial in the morning before mid-week HD section for analysis of inflammatory cytokines (serum IL-1β, IL-18, and TNF-α levels) and oxidative stress (TBARS, Total antioxidant status and serum 8-OHdG). Participants with sleep disturbance will be randomized into CBT group and control group in 1:1 ratio and all of them receive sleep hygiene education before the trial. Participants who randomized into the CBT group will receive 6 1-hour weekly treatment sessions of CBT during the 6-week period. Participants who received hypnotics chronically before being recruited were maintained at the same dose of hypnotics during the therapy. After the 6-week trail, all participants will receive PSQI, FSS, BDI, IIEF, IFSF and BRS again and 2nd blood sampling for analysis of inflammatory cytokine and oxidative stress again. All the questionnaires, BRS and analyses of inflammatory cytokine and oxidative stress will be performed again 3 months after the trial for the long-term follow-up analysis. The details of investigation are demonstrated in Figure 1.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis and Its Impacts on Their Inflammatory Cytokines, Oxidative Stress and Autonomic Dysfunction
Study Start Date :
Aug 1, 2009
Anticipated Primary Completion Date :
Sep 1, 2010
Anticipated Study Completion Date :
Sep 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: cognitive behaviorial therapy

Behavioral: cognitive behavioral therapy
Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
Other Names:
  • cognitive behavioral therpy
  • Outcome Measures

    Primary Outcome Measures

    1. improvement of sleep disturbance/depression/anxiety [6 weeks]

    Secondary Outcome Measures

    1. Changes of inflammatory cytokines/oxidative stress [6 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • under maintenance hemodialysis for more than 6 months

    • subjective sleep complaints and screening PSQI ≥ 5

    Exclusion Criteria:
    • active medical condition (hospitalization/surgery)

    • active malignancy

    • active infection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Far Eastern Memorial Hospital Taipei Taiwan 220

    Sponsors and Collaborators

    • Far Eastern Memorial Hospital

    Investigators

    • Principal Investigator: Hung-Yuan Chen, M.D, Far Eastern Memorial Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01159197
    Other Study ID Numbers:
    • FEMH-97-D-093
    First Posted:
    Jul 9, 2010
    Last Update Posted:
    Aug 6, 2010
    Last Verified:
    Nov 1, 2008

    Study Results

    No Results Posted as of Aug 6, 2010